← Back to home

MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable)

Clinical trials for MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) explained in plain language.

Never miss a new study

Get alerted when new MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) trials appear

Sign up with your email to follow new studies for MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Could a targeted drug make stem cell transplants more effective for tough blood cancers?

Disease control Ongoing

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood…

Matched conditions: MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE)

Phase 1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control

Last updated Jun 27, 2026 12:35 UTC

MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable)

Get alerted when new MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) trials appear

Could a targeted drug make stem cell transplants more effective for tough blood cancers?